All In Biotech

Drug Trial Radar · NCT06667141

Study of ACR-2316 in Specific Advanced Solid Tumors

ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 8, 2024

Primary completion

Aug 12, 2027

Study completion Dec 12, 2027

Sponsor

Lead sponsor
Acrivon TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in-human, Open-label Phase 1/2 study to assess the safety and activity of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

Conditions

  • Specific Advanced Solid Tumors

Interventions

  • ACR-2316Drug

    ACR-2316 is an experimental drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose EscalationTime frame: Number of DLT events during the DLT observation period (up to 28 days)
  2. Dose ExpansionTime frame: RP2D supported by safety, PK and PD data through study completion
  3. Dose ExpansionTime frame: Incidence and grades of TEAEs and TRAEs per NCI CTCAE v.5.0 and number of dose decreases, number of dose delays, and SAEs through study completion, an average of 1 year.
  4. Dose ExpansionTime frame: Confirmed ORR per Recist v1.1 and DOR, CBR, assessed every 6 weeks from baseline thorough study completion, an average 1 year or until death.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Phoenix, Arizona · Recruiting

  • Precision NextGen Oncology & Research Center

    Beverly Hills, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • Denver Health One

    Denver, Colorado · Recruiting

  • Florida Cancer Specialist

    Sarasota, Florida · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Montefiore Medical Centre

    The Bronx, New York · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Tennessee Oncology

    Franklin, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • Next Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.